New Breast Cancer Drug Negotiated – Thanks To You

breast cancer drugs ribociclib Canada approval

Good morning fellow allies.

We’re thrilled to report a new treatment for metastatic breast cancer has just been negotiated at pCPA, bringing it one step closer to the women who need it. For women living with MBC, swift access to treatments means more time and the potential to live a better life longer.

That’s why last fall we called on the Rethink community to be allies for women living with MBC. Amazingly, nearly 2,000 of you answered with your pledge.

This isn’t the first time our community has shown how passionate and dedicated they are about this cause. We’ve come a long way and have done a lot of hard work together. That deserves some recognition. Here’s a reminder of where we’ve been and what we’ve accomplished.

October 2017: 10,000 Rethinkers Make A Commitment To Women Living With MBC
breast cancer drug

10,000 rethinkers signed the #MBCinthedark petition, committing to making our health system better for everyone by bring the voices and values of women with metastatic breast cancer into the light.

October 19, 2017: Rethink Heads To Queen’s Park
breast cancer drug

With the strength of our petition signers, Rethink and over 40 advocates represented the MBC community in Queen’s Park to bring greater visibility to the reality of unknowns that those with metastatic breast cancer currently face.

September 2018:The pCPA Announces New Benchmarks

The pCPA announces their benchmarks for shorter timelines to negotiate drug prices and sign a letter of intent.

October 2018: You Answer Our Call For Allies
breast cancer drug negotiated

We called for 1,000 allies to help keep governing bodies and drug manufacturers accountable to these newly announced benchmarks. Nearly 2,000 of you answer the call.

October 25, 2018: Rethink Heads Back To Queen’s Park
breast cancer drug

Rethink headed to Queen’s Park with more than 40 advocates to show decision makers that we are watching, and ready to move if benchmarks and promises weren’t kept.

November 2018 – April 2019: Rethink Keeps Pressure On pCPA And Drug Manufacturer
breast cancer drug

The Rethink team works behind the scenes to keep the pressure on the pCPA and the manufacturer through meetings and calls with key stakeholders.  Although we play a role as a trusted partner, having nearly 2,000 allies who are counting on them to uphold their commitments, helps strengthen our voice.

May 2019: Progress Is Made For New Breast Cancer Drug Kisqali (Ribociclib)
breast cancer drug

Proof your voice can make a difference. The manufacturer and pCPA have negotiated a drug price and signed a letter of intent for Kisqali (ribociclib). This was done in half the time it took to for the last breast cancer drug to be negotiated.

I know that during periods of waiting it can feel as though progress and change are out of reach. It can be hard to understand where your voice fits in the conversation and if it can make a lasting impact.

This most recent win is proof that your voice can make a difference. Together, we can create a groundswell of support ensuring that MBC voices can be heard.

So, we thank you for your pledge and your willingness to stand up for women with MBC when they need it most.  Because until there is a cure, it is access treatments that give them time and help them live a better life longer.


Want to become an Ally to women living with MBC? Sign the pledge here.

You may also be interested in

WIG OUT: Fitting and caring for wigs
#YWBC Profile: Josee Daoust
Fact or Fiction: Carcinogens
50 Carroll Street Toronto, Ontario Canada M4M 3G3
Phone: 416 220 0700
Registered Charity #: 892176116RR0001

Join Our Movement

Follow Us

Donate Now

You can make a positive impact in the lives of people impacted by breast cancer